Foresite Capital Management VI LLC — 13F Holdings & Portfolio
CIK 2013341 · latest 13F-HR filed 2026-05-15
Foresite Capital Management VI LLC manages $460.3M in 13F-reported U.S. long-equity assets across 17 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are CGON (32.67%), ALMS (20.33%), CNTA (11.77%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 8 new positions, exited 3, added to 8, and trimmed 1.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$460.3M
Long-equity book
17
Distinct positions
2026-03-31
Filed 2026-05-15
+8 / −3 / ↑8 / ↓1
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- CG Oncology, Inc.$58.1M +63.0%
- ALUMIS INC.$52.1M +125.7%
- Centessa Pharmaceuticals plc$20.1M +58.8%
- Corvus Pharmaceuticals, Inc.$16.2M +151.9%
- Denali Therapeutics Inc.$6.7M +40.7%
New Positions
- Minerva Neurosciences, Inc.$12.0M
- Celldex Therapeutics, Inc.$10.0M
- AtaiBeckley Inc.$9.7M
- Crinetics Pharmaceuticals, Inc.$7.7M
- OnKure Therapeutics, Inc.$6.0M
Exited Positions
- RAPT Therapeutics, Inc.$52.9M
- Natera, Inc.$15.4M
- Atai Beckley N.V.$11.2M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CG Oncology, Inc. | CGON | 156944100 | $150.3M | 32.67% | 2,221,474 | SH |
| 2 | ALUMIS INC. | ALMS | 022307102 | $93.6M | 20.33% | 4,247,670 | SH |
| 3 | Centessa Pharmaceuticals plc | CNTA | 152309100 | $54.2M | 11.77% | 1,364,019 | SH |
| 4 | Corvus Pharmaceuticals, Inc. | CRVS | 221015100 | $26.8M | 5.82% | 1,831,233 | SH |
| 5 | Denali Therapeutics Inc. | DNLI | 24823R105 | $23.2M | 5.05% | 1,209,971 | SH |
| 6 | AGIOS PHARMACEUTICALS, INC. | AGIO | 00847X104 | $17.8M | 3.86% | 525,000 | SH |
| 7 | Verastem, Inc. | VSTM | 92337C203 | $16.7M | 3.62% | 3,146,631 | SH |
| 8 | Kymera Therapeutics, Inc. | KYMR | 501575104 | $12.2M | 2.65% | 146,332 | SH |
| 9 | Minerva Neurosciences, Inc. | NERV | 603380205 | $12.0M | 2.60% | 1,986,600 | SH |
| 10 | Celldex Therapeutics, Inc. | CLDX | 15117B202 | $10.0M | 2.18% | 315,913 | SH |
| 11 | AtaiBeckley Inc. | ATAI | 04650F101 | $9.7M | 2.12% | 2,750,000 | SH |
| 12 | Hinge Health, Inc. | HNGE | 433313103 | $8.5M | 1.85% | 220,400 | SH |
| 13 | Crinetics Pharmaceuticals, Inc. | CRNX | 22663K107 | $7.7M | 1.67% | 212,010 | SH |
| 14 | OnKure Therapeutics, Inc. | OKUR | 68277Q105 | $6.0M | 1.30% | 1,445,783 | SH |
| 15 | Jade Biosciences, Inc. | JBIO | 008064206 | $4.5M | 0.98% | 320,000 | SH |
| 16 | GH Research PLC | GHRS | G3855L106 | $4.4M | 0.96% | 315,492 | SH |
| 17 | Zura Bio Ltd | ZURA | G9TY5A101 | $2.7M | 0.58% | 450,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $460.3M | 17 | 0001104659-26-062467 |
| 2025-12-31 | 2026-02-17 | $330.8M | 12 | 0001104659-26-015412 |
| 2025-09-30 | 2025-11-14 | $258.9M | 12 | 0001104659-25-112509 |